Researchers in the UK have shown that guanfacine could help to combat leftward spatial exploration deficit in patients with visual neglect due to right-hemisphere stroke. The noradrenergic ...
The Dementia Trials Accelerator (DTA) – which will be spearheaded by the UK Dementia Research Institute (UK DRI) and Health ...
The World Anti-Doping Agency (WADA) has announced the 2025 List of Prohibited Substances and Methods, including the Summary ...
There are currently three non-stimulant ADHD medications that the FDA has approved for adults and children: atomoxetine, clonidine, and guanfacine. Atomoxetine, which is usually marketed under the ...
For users of guanfacine it is advised not to stop suddenly, however, it is “usually safe” to stop medications such as methylphenidate, lisdexamfetamine and atomoxetine without needing to ...
National Patient Safety Alert (NatPSA) : Issued on 27 September 2023, highlighting shortages of methylphenidate prolonged-release capsules and tablets, lisdexamfetamine capsules, and guanfacine ...
It affects more than 8% of children and 2.5% of adults. In children, ADHD can impact many aspects of everyday life, including ...
Hydrafinil is now classified as a non-specified stimulant. • It is clarified that guanfacine is not a prohibited substance. • Beta-blockers are no longer prohibited in any skiing and snowboarding ...
There are also non-stimulants, in particular atomoxetine and guanfacine, which are used less often but can also be highly effective. Non-stimulants can be prescribed by GPs but this may not always be ...
Tourette syndrome is a neurological (nervous system) tic disorder. It causes people to make sudden movements or sounds they can’t control. These are called tics. For example, someone with ...
The International Tennis Integrity Agency (ITIA) has reacted this week to the Prohibited List published in September by the ...
Adults with attention-deficit/hyperactivity disorder (ADHD) are more frequently presenting for diagnosis and treatment. Medication is considered to be appropriate ...